Show simple item record

The beneficial effect of tamoxifen on serum lipoprotein-a levels: An additional anti-atherogenic property

dc.contributor.authorElisaf, Moses S.en
dc.contributor.authorBairaktari, Eleni Then
dc.contributor.authorNikolaides, C.en
dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorTzallas, C. S.en
dc.contributor.authorSiamopoulos, K. C.en
dc.contributor.authorTsolas, O.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorElisaf, Moses S.en
dc.creatorBairaktari, Eleni Then
dc.creatorNikolaides, C.en
dc.creatorFountzilas, Georgeen
dc.creatorTzallas, C. S.en
dc.creatorSiamopoulos, K. C.en
dc.creatorTsolas, O.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:52:59Z
dc.date.available2018-06-22T09:52:59Z
dc.date.issued1996
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41603
dc.description.abstractIt has recently been suggested that increased lipoprotein (a) levels are an independent risk factor for coronary heart disease. It has also been reported that tamoxifen can induce changes in blood lipid values. In this prospective study we investigated the long term effects tamoxifen on the lipid profile, focusing on lipoprotein(a) levels. Thirty-eight postmenopausal women with breast cancer treated with tamoxifen at a dose of 20 mg daily were studied. The mean age was 61 years. Serum lipoprotein(a) levels and lipid parameters (total cholesterol, high and low density lipoprotein cholesterol, triglycerides, apolipoprotein A-I and B) were measured after an overnight fast on the 1, 3, 6 and 9 month of tamoxifen treatment. A progressive fall in median lipoprotein(a) levels from 8 mg/dl to 3 mg/dl (p < 0.001) was observed. In addition, a significant decrease in the total and low density lipoprotein cholesterol and in apolipoprotein B, as well as an increase in apolipoprotein A-l were also noticed. It is concluded that our data on serum lipoprotein(a) levels agree with the beneficial anti-atherogenic effects of tamoxifen administration on lipoproteins.en
dc.language.isoengen
dc.sourceAnticancer Researchen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast canceren
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectPriority journalen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectDrug effecten
dc.subjectProspective studiesen
dc.subjectProspective studyen
dc.subjectRisk factoren
dc.subjectCholesterolen
dc.subjectLdlen
dc.subjectLow density lipoprotein cholesterolen
dc.subjectTriacylglycerolen
dc.subjectAntilipemic agentsen
dc.subjectApolipoprotein a1en
dc.subjectApolipoprotein ben
dc.subjectAtherogenesisen
dc.subjectCholesterolen
dc.subjectCholesterol blood levelen
dc.subjectHdlen
dc.subjectHigh density lipoprotein cholesterolen
dc.subjectIschemic heart diseaseen
dc.subjectLipid parametersen
dc.subjectLipoprotein aen
dc.subjectLipoprotein blood levelen
dc.subjectLipoprotein(a)en
dc.subjectPostmenopauseen
dc.subjectTamoxifenen
dc.subjectTriacylglycerol blood levelen
dc.titleThe beneficial effect of tamoxifen on serum lipoprotein-a levels: An additional anti-atherogenic propertyen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume16
dc.description.issue5 Aen
dc.description.startingpage2725
dc.description.endingpage2728
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidElisaf, Moses S. [0000-0003-0505-078X]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0003-0505-078X


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record